0	3	The	the	DT
4	9	c-rel	c-rel	NN
10	23	protooncogene	protooncogene	NN
24	31	product	product	NN
32	41	represses	repress	VBZ
42	50	NF-kappa	NF-kappa	NNP
51	52	B	B	NNP
53	65	p65-mediated	p65-mediated	JJ
66	81	transcriptional	transcriptional	JJ
82	92	activation	activation	NN
93	95	of	of	IN
96	99	the	the	DT
100	104	long	long	JJ
105	113	terminal	terminal	JJ
114	120	repeat	repeat	NN
121	123	of	of	IN
124	128	type	type	NN
129	130	1	1	CD
131	136	human	human	JJ
137	153	immunodeficiency	immunodeficiency	NN
154	159	virus	virus	NN
159	160	.	.	.

162	165	The	the	DT
166	170	long	long	JJ
171	179	terminal	terminal	JJ
180	186	repeat	repeat	NN
187	188	(	(	(
188	191	LTR	LTR	NNP
191	192	)	)	)
193	195	of	of	IN
196	199	the	the	DT
200	204	type	type	NN
205	206	1	1	CD
207	212	human	human	JJ
213	229	immunodeficiency	immunodeficiency	NN
230	235	virus	virus	NN
236	237	(	(	(
237	242	HIV-1	HIV-1	NNP
242	243	)	)	)
244	247	and	and	CC
248	251	the	the	DT
252	253	5	5	CD
253	254	’	'	SYM
255	265	regulatory	regulatory	JJ
266	272	region	region	NN
273	275	of	of	IN
276	279	the	the	DT
280	284	gene	gene	NN
285	293	encoding	encode	VBG
294	297	the	the	DT
298	309	interleukin	interleukin	NN
310	311	2	2	CD
312	320	receptor	receptor	NN
321	326	alpha	alpha	NN
327	334	subunit	subunit	NN
335	336	(	(	(
336	341	IL-2R	IL-2R	NNP
342	347	alpha	alpha	NN
347	348	)	)	)
349	354	share	share	VBP
355	365	functional	functional	JJ
366	371	kappa	kappa	NN
372	373	B	B	NNP
374	382	enhancer	enhancer	NN
383	391	elements	element	NNS
392	400	involved	involve	VBN
401	403	in	in	IN
404	407	the	the	DT
408	418	regulation	regulation	NN
419	421	of	of	IN
422	427	these	these	DT
428	437	inducible	inducible	JJ
438	451	transcription	transcription	NN
452	457	units	unit	NNS
458	464	during	during	IN
465	471	T-cell	t-cell	NN
472	482	activation	activation	NN
482	483	.	.	.

484	489	These	these	DT
490	495	kappa	kappa	NN
496	497	B	B	NNP
498	506	enhancer	enhancer	NN
507	515	elements	element	NNS
516	519	are	be	VBP
520	530	recognized	recognize	VBN
531	533	by	by	IN
534	535	a	a	DT
536	548	structurally	structurally	RB
549	556	related	related	JJ
557	563	family	family	NN
564	566	of	of	IN
567	578	interactive	interactive	JJ
579	587	proteins	protein	NNS
588	592	that	that	WDT
593	601	includes	include	VBZ
602	605	p50	p50	NN
605	606	,	,	,
607	610	p65	p65	NN
610	611	,	,	,
612	615	and	and	CC
616	619	the	the	DT
620	627	product	product	NN
628	630	of	of	IN
631	634	the	the	DT
635	640	c-rel	c-rel	NN
641	654	protooncogene	protooncogene	NN
655	656	(	(	(
656	661	c-Rel	c-rel	NN
661	662	)	)	)
662	663	.	.	.

664	670	Recent	recent	JJ
671	682	biochemical	biochemical	JJ
683	690	studies	study	NNS
691	695	have	have	VBP
696	701	shown	show	VBN
702	706	that	that	IN
707	710	p65	p65	NN
711	714	and	and	CC
715	718	p50	p50	NN
719	723	form	form	VBP
724	727	the	the	DT
728	740	prototypical	prototypical	JJ
741	749	NF-kappa	NF-kappa	NNP
750	751	B	B	NNP
752	759	complex	complex	NN
759	760	,	,	,
761	766	which	which	WDT
767	769	is	be	VBZ
770	777	rapidly	rapidly	RB
778	790	translocated	translocate	VBN
791	795	from	from	IN
796	799	the	the	DT
800	809	cytoplasm	cytoplasm	NN
810	812	to	to	TO
813	816	the	the	DT
817	824	nucleus	nucleus	NN
825	831	during	during	IN
832	838	T-cell	t-cell	NN
839	849	activation	activation	NN
849	850	.	.	.

851	855	This	this	DT
856	869	intracellular	intracellular	JJ
870	879	signaling	signaling	NN
880	887	complex	complex	NN
888	896	potently	potently	RB
897	907	stimulates	stimulate	VBZ
908	913	kappa	kappa	NN
914	924	B-directed	b-directed	JJ
925	938	transcription	transcription	NN
939	943	from	from	IN
944	950	either	either	CC
951	954	the	the	DT
955	960	HIV-1	HIV-1	NNP
961	964	LTR	LTR	NNP
965	967	or	or	CC
968	971	the	the	DT
972	977	IL-2R	IL-2R	NNP
978	983	alpha	alpha	NN
984	992	promoter	promoter	NN
993	996	via	via	IN
997	1000	the	the	DT
1001	1007	strong	strong	JJ
1008	1023	transactivation	transactivation	NN
1024	1030	domain	domain	NN
1031	1038	present	present	JJ
1039	1041	in	in	IN
1042	1045	p65	p65	NN
1045	1046	.	.	.

1047	1049	We	we	PRP
1050	1053	now	now	RB
1054	1065	demonstrate	demonstrate	VBP
1066	1070	that	that	IN
1071	1078	nuclear	nuclear	JJ
1079	1089	expression	expression	NN
1090	1092	of	of	IN
1093	1098	human	human	JJ
1099	1104	c-Rel	c-rel	NN
1104	1105	,	,	,
1106	1111	which	which	WDT
1112	1114	is	be	VBZ
1115	1122	induced	induce	VBN
1123	1125	by	by	IN
1126	1132	either	either	CC
1133	1140	phorbol	phorbol	NN
1141	1146	ester	ester	NN
1147	1149	or	or	CC
1150	1155	tumor	tumor	NN
1156	1164	necrosis	necrosis	NN
1165	1171	factor	factor	NN
1172	1177	alpha	alpha	NN
1178	1182	with	with	IN
1183	1190	delayed	delay	VBN
1191	1199	kinetics	kinetic	NNS
1200	1208	relative	relative	JJ
1209	1211	to	to	TO
1212	1215	p65	p65	NN
1215	1216	,	,	,
1217	1225	markedly	markedly	RB
1226	1235	represses	repress	VBZ
1236	1248	p65-mediated	p65-mediated	JJ
1249	1259	activation	activation	NN
1260	1262	of	of	IN
1263	1268	these	these	DT
1269	1282	transcription	transcription	NN
1283	1288	units	unit	NNS
1288	1289	.	.	.

1290	1295	These	these	DT
1296	1306	inhibitory	inhibitory	JJ
1307	1314	effects	effect	NNS
1315	1317	of	of	IN
1318	1323	c-Rel	c-rel	NN
1324	1333	correlate	correlate	VBP
1334	1338	with	with	IN
1339	1342	its	its	PRP$
1343	1354	DNA-binding	dna-binding	JJ
1355	1363	activity	activity	NN
1364	1367	but	but	CC
1368	1371	not	not	RB
1372	1376	with	with	IN
1377	1380	its	its	PRP$
1381	1388	ability	ability	NN
1389	1391	to	to	TO
1392	1406	heterodimerize	heterodimerize	VB
1407	1411	with	with	IN
1412	1415	p50	p50	NN
1415	1416	,	,	,
1417	1427	suggesting	suggest	VBG
1428	1432	that	that	IN
1433	1438	c-Rel	c-rel	NN
1439	1449	inhibition	inhibition	NN
1450	1458	involves	involve	VBZ
1459	1470	competition	competition	NN
1471	1475	with	with	IN
1476	1483	p50/p65	p50/p65	NN
1484	1487	for	for	IN
1488	1497	occupancy	occupancy	NN
1498	1500	of	of	IN
1501	1504	the	the	DT
1505	1510	kappa	kappa	NN
1511	1512	B	B	NNP
1513	1521	enhancer	enhancer	NN
1522	1529	element	element	NN
1529	1530	.	.	.

1531	1539	Together	together	RB
1539	1540	,	,	,
1541	1546	these	these	DT
1547	1555	findings	finding	NNS
1556	1563	suggest	suggest	VBP
1564	1568	that	that	IN
1569	1572	one	one	CD
1573	1581	function	function	NN
1582	1584	of	of	IN
1585	1590	c-Rel	c-rel	NN
1591	1593	is	be	VBZ
1594	1596	as	as	IN
1597	1598	a	a	DT
1599	1610	physiologic	physiologic	JJ
1611	1620	repressor	repressor	NN
1621	1623	of	of	IN
1624	1627	the	the	DT
1628	1633	HIV-1	HIV-1	NNP
1634	1637	LTR	LTR	NNP
1638	1641	and	and	CC
1642	1647	IL-2R	IL-2R	NNP
1648	1653	alpha	alpha	NN
1654	1663	promoters	promoter	NNS
1663	1664	,	,	,
1665	1672	serving	serve	VBG
1673	1675	to	to	TO
1676	1687	efficiently	efficiently	RB
1688	1695	counter	counter	VB
1696	1699	the	the	DT
1700	1706	strong	strong	JJ
1707	1722	transcriptional	transcriptional	JJ
1723	1733	activating	activate	VBG
1734	1741	effects	effect	NNS
1742	1744	of	of	IN
1745	1748	p65	p65	NN
1748	1749	.	.	.